Telmisartan protects against insulin resistance by attenuating inflammatory response in rats

Abstract

This study investigated the effects of telmisartan on insulin resistance in high-fat diet-treated rats and the possible mechanism. A total of 40 male Sprague-Dawley rats enrolled in the study were divided into 4 groups at random: ND group (n=10) and HD group (n=10), in which the rats were given a normal chow diet or a high-fat diet for 20 weeks following a one-week adaptation; ND+telmisartan (n=10) group and HD+telmisartan group (n=10), in which the rats were initially administered in the same way as the ND or HD group, and then they were orally gavaged with telmisartan (5 mg/kg daily) additionally for 5 weeks. Related inflammatory factors were measured by ELISA. Monocyte chemotactic protein 1 (MCP-1), phosphorylated JNK and IκB-α expressions in both adipose and liver were detected by Western blotting. CRP and angiotensin II receptor 1 (AT1) mRNA expressions in both adipose and liver were determined by RT-PCR. The results showed that telmisartan administration in vivo reversed insulin resistance as evidenced by a decrease in plasma fasting glucose levels, plasma fasting insulin levels and homeostasis model of assessment-insulin resistance (HOMA-IR). Furthermore, telmisartan administration significantly reduced serum CRP, TNF-α and IL-1β levels, and elevated serum IL-10 levels. It was also found to hamper the high-fat diet-induced increase in CRP mRNA, AT1 mRNA and MCP-1, and decrease in IκB-α in both adipose and liver. It was concluded that telmisartan administration in vivo may improve insulin resistance through attenuated inflammatory response pathways.

Keywords

telmisartan / insulin resistance / inflammation / obesity

References

[1] KurtzT.W.. Beyond the classic angiotensin-receptorblocker profile. Nat Clin Pract Cardiovasc Med, 2008, 5(Suppl1): S19-26

[2] AndrawsR., BrownD.L.. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol, 2007, 99(7): 1006-1012

[3] McMurrayJ.J., HolmanR.R., HaffnerS.M., et al.. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med, 2010, 362(16): 1477-1490

[4] SugimotoK., QiN.R., KazdováL., et al.. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension, 2006, 47(5): 1003-1009

[5] HeH., YangD., MaL., et al.. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways. Hypertension, 2010, 55(4): 869-879

[6] Rong X, Li Y, Ebihara K, et al. Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia, 2010 [PMID: 20390403]

[7] ZanchiA., DullooA.G., PerregauxC., et al.. Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. Am J Physiol Endocrinol Metab, 2007, 293(1): E91-E95

[8] ShimabukuroM., TanakaH., ShimabukuroT.. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens, 2007, 25(4): 841-848

[9] NegroR., FormosoG., HassanH.. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest, 2006, 29(11): 957-961

[10] EnjojiM., KotohK., KatoM., et al.. Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study. Int J Mol Med, 2008, 22(4): 521-527

[11] LiangH., YinB., ZhangH., et al.. Blockade of tumor necrosis factor (TNF) receptor type 1-mediated TNF-alpha signaling protected Wistar rats from diet-induced obesity and insulin resistance. Endocrinology, 2008, 149(6): 2943-2951

[12] XuX., ZhaoC.X., WangL., et al.. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes, 2010, 59(4): 997-1005

[13] BensonS.C., PershadsinghH.A., HoC.I., et al.. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension, 2004, 43(5): 993-1002

[14] ZhaoC., WangP., XiaoX., et al.. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension, 2003, 42(5): 1026-1033

[15] TuL., XuX., WanH., et al.. Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats. Hum Gene Ther, 2008, 19(4): 318-330

[16] TamC.S., ViardotA., ClémentK., et al.. Short-term overfeeding may induce peripheral insulin resistance without altering subcutaneous adipose tissue macrophages in humans. Diabetes, 2010, 59(9): 2164-2170

[17] HausJ.M., SolomonT.P., MarchettiC.M., et al.. Free fatty acid-induced hepatic insulin resistance is attenuated following lifestyle intervention in obese individuals with impaired glucose tolerance. J Clin Endocrinol Metab, 2010, 95(1): 323-327

[18] TzotzasT., PapadopoulouF.G., TziomalosK., et al.. Rising serum 25-hydroxy-vitamin D levels after weight loss in obese women correlate with improvement in insulin resistance. J Clin Endocrinol Metab, 2010, 95(9): 4251-4257

[19] OlefskyJ.M., GlassC.K.. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol, 2010, 72: 219-246

[20] XuJ.W., MoritaI., IkedaK., et al.. C-reactive protein suppresses insulin signaling in endothelial cells: role of spleen tyrosine kinase. Mol Endocrinol, 2007, 21(2): 564-573

[21] SolomonS.S., OdunusiO., CarriganD., et al.. TNF-alpha inhibits insulin action in liver and adipose tissue: A model of metabolic syndrome. Horm Metab Res, 2010, 42(2): 115-121

[22] JagerJ., GremeauxT., CormontM., et al.. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology, 2007, 148(1): 241-251

[23] OsbornO., BrownellS.E., Sanchez-AlavezM., et al.. treatment with an interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine, 2008, 44(1): 141-148

[24] EhsesJ.A., LacrazG., GiroixM.H., et al.. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA, 2009, 106(33): 13 998-14 003

[25] OwyangAM, MaedlerK, GrossL, et al.. XOMA 052, an anti-IL-1ta monoclonal antibody, improves glucose control and ta-cell function in the diet-induced obesity mouse model. Endocrinology, 2010, 151(6): 2515-2527

[26] CintraD.E., PauliJ.R., AraújoE.P., et al.. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol, 2008, 48(4): 628-637

[27] HongE.G., KoH.J., ChoY.R., et al.. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes, 2009, 58(11): 2525-2535

[28] Fernandez-VeledoS., Vila-BedmarR., Nieto-VazquezI., et al.. c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists. J Clin Endocrinol Metab, 2009, 94(9): 3583-3593

[29] DrazninB.. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes, 2006, 55(8): 2392-2397

[30] SartipyP., LoskutoffD.J.. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A, 2003, 100(12): 7265-7270

[31] KandaH., TateyaS., TamoriY., et al.. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest, 2006, 116(6): 1494-1505

[32] BarnesP.J., KarinM.. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997, 336(15): 1066-1071

[33] ItaniS.I., RudermanN.B., SchmiederF., et al.. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes, 2002, 51(7): 2005-2011

[34] GoyalS., AroraS., BhattT.K., et al.. Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes. Chem Biol Interact, 2010, 185(3): 271-280

[35] IwanamiJ., MogiM., TsukudaK., et al.. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. J Hypertens, 2010, 28(8): 1730-1737

[36] ClemenzM., FrostN., SchuppM., et al.. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes, 2008, 57(5): 1405-1413

[37] Feng X, Luo Z, Ma L, et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR delta/ AMPK pathway. J Cell Mol Med, 2010 [PMID:20477906]

[38] PrasadA., QuyyumiA.A.. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation, 2004, 110(11): 1507-1512